Racial and Geographic Disparities in the Utilization of Surgical Therapy for Hepatocellular Carcinoma
First Online: 03 October 2007 Received: 20 May 2007 Accepted: 24 August 2007 DOI:
10.1007/s11605-007-0315-8 Cite this article as: Sonnenday, C.J., Dimick, J.B., Schulick, R.D. et al. J Gastrointest Surg (2007) 11: 1636. doi:10.1007/s11605-007-0315-8 Abstract
The incidence of hepatocellular carcinoma (HCC) continues to increase, a trend that will likely continue because of the rising prevalence of chronic hepatitis C infection. This study sought to determine the recent patterns of utilization of surgical therapy (hepatectomy, ablation, or liver transplantation) for HCC from the Surveillance, Epidemiology, and End Results national cancer registry. Data were extracted for 16,121 patients with HCC diagnosed between 1998 and 2004. Twenty-three percent of patients underwent surgical therapy (9.5% resection, 7.8% ablation, 6% transplant); the proportion of patients treated with surgical therapy increased ∼9% over the study period. On multivariate analysis, female sex, younger age, and smaller solitary tumors were associated with increased utilization of surgical therapy. Blacks and Hispanics were 24–27% less likely to receive surgical therapy than white individuals (
P < 0.001). Racial and geographic disparities persisted despite the adjustment for Health Service Area and limitation of the cohort to small localized HCC. Blacks were especially disadvantaged in the utilization of liver transplant for small HCC (OR = 0.42, P < 0.001). Further investigation to understand the etiology of these profound racial and geographic disparities is essential to ensure equitable provision of surgical therapies, which provide the only potentially curative treatments for HCC. Keywords Hepatocellular cancer Racial disparity Geographic disparity Liver transplantation Surgery
Presented at the 48th Annual Meeting of the Society of Surgery of the Alimentary Tract, Digestive Disease Week 2007, Washington, DC.
Bosch FX, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127(5 supp 1):S5–16.
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745–750.
Ries LAG, et al. SEER Cancer Statistics Review, 1975–2004. Bethesda, MD: National Cancer Insititute; 2007.
El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001;5(1):87–107. vi.
Davila JA, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127(5):1372–1380.
Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40(3):225–235.
Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):181–200.
Cha CH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238(3):315–321. discussion 321–323.
Shiina S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology. 2005;129(1):122–130.
Lin SM, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology. 2004;127(6):1714–1723.
Livraghi T, et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210(3):655–661.
Marrero JA, Pelletier S. Hepatocellular carcinoma. Clin Liver Dis. 2006;10(2):339–51. ix.
Hemming AW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233(5):652–659.
Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–699.
National Center for Health Statistics (US). Atlas of United States Mortality NCHS Atlas CD-ROM No.1. Hyattsville, MD: Dept. of Health and Human Services; 1997.
Makuc DM, et al. Health service areas for the United States. Vital Health Stat. 1991;2(112):1–102.
Makuc DM, et al. The use of health service areas for measuring provider availability. J Rural Health. 1991;7(4 supp):347–356.
Cha C, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197(5):753–758.
Fong Y, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229(6):790–799. discussion 799–800.
Yao FY, et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8(9):765–774.
Yao FY, Roberts JP. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time? Liver Transpl. 2004;10(7):919–921.
Yao FY, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005;11(12):1505–1514.
Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc. 2006;98(12):1934–1939.
Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol. 2006;4(1):104–110. quiz 4–5.
El-Serag HB, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44(1):158–166.
Morris AM, et al. Racial disparities in late survival after rectal cancer surgery. J Am Coll Surg. 2006;203(6):787–794.
Dominitz JA, et al. Race, treatment, and survival of veterans with cancer of the distal esophagus and gastric cardia. Med Care. 2002;40(1 supp):I14–I26.
Eloubeidi MA, et al. Prognostic factors for survival in pancreatic cancer: a population-based study. Am J Surg. 2006;192(3):322–329.
Smedley BD, et al. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care, vol xvi. Washington, DC: National Academies; 2003. p. 764.
Dartmouth Medical School. Center for the Evaluative Clinical Sciences. The Dartmouth Atlas of Health Care 1998, 1 Atlas. Chicago, IL: American Hospital; 1998. 305 pp.
Skinner J, et al. Racial, ethnic, and geographic disparities in rates of knee arthroplasty among Medicare patients. N Engl J Med. 2003;349(14):1350–1359.
Weinstein JN, et al. United States’ trends and regional variations in lumbar spine surgery: 1992–2003. Spine. 2006;31(23):2707–2714.
Pope GD, Birkmeyer JD, Finlayson SR. National trends in utilization and in-hospital outcomes of bariatric surgery. J Gastrointest Surg. 2002;6(6):855–860. discussion 861.
Dimick JB, Finlayson SR, Birkmeyer JD. Regional availability of high-volume hospitals for major surgery. Health Aff (Millwood) 2004;Suppl Web Exclusives:VAR45–VAR53.
Finlayson SR, et al. Patient preferences for location of care: implications for regionalization. Med Care. 1999;37(2):204–209.
Baicker K, Chandra A, Skinner JS. Geographic variation in health care and the problem of measuring racial disparities. Perspect Biol Med. 2005;48(1 supp):S42–53.
Reid AE, et al. Disparity in use of orthotopic liver transplantation among blacks and whites. Liver Transpl. 2004;10(7):834–841.
Powe NR, Boulware LE. The uneven distribution of kidney transplants: getting at the root causes and improving care. Am J Kidney Dis. 2002;40(4):861–863.
Pomfret EA, et al. Liver and intestine transplantation in the United States, 1996–2005. Am J Transplant. 2007;7(supp 1):1376–1389.
Bruix J, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998;27(6):1578–1583.
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442.
PubMed CrossRef Copyright information
© The Society for Surgery of the Alimentary Tract 2007